Aditxt, Inc. Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs
Aditxt, Inc. (ADTX) reported Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs of $100.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-20.
Discontinued › Expense Statement › Operating Expenses
srt:ExtensionsDiscoveriesAdditionsAndImprovedRecoveryLessRelatedCosts · last filed 2024-05-20
- Aditxt, Inc. extensions, discoveries, additions and improved recovery, less related costs for the quarter ending 2024-03-31 was $100.00K, a 0.00% change year-over-year.
- Aditxt, Inc. extensions, discoveries, additions and improved recovery, less related costs for the quarter ending 2023-03-31 was $100.00K.
- Aditxt, Inc. extensions, discoveries, additions and improved recovery, less related costs for fiscal 2023 was $100.00K.
| Period end | Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs | Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs 1 month | Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs 3 month | Extensions, Discoveries, Additions and Improved Recovery, Less Related Costs 12 month |
|---|---|---|---|---|
| 2024-03-31 | $100.00K 10-Q · filed 2024-05-20 | |||
| 2023-12-31 | $100.00K 10-K · filed 2024-04-16 | |||
| 2023-03-31 | $100.00K 10-K · filed 2024-04-16 | $100.00K 10-Q · filed 2024-05-20 | ||
| 2022-03-31 | $100.00K 10-Q · filed 2023-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |